131
http://www.DGS-PraxisLeitlinien.deNr.
Nachweis
85
Fainsinger RL, Nekolaichuk C, Lawlor P, Hagen N, Bercovitch M, Fisch M, Galloway L, Kaye
G, Landman W, Spruyt O, Zhukovsky D, Bruera E, Hanson J. An international multicentre
validation study of a pain classification system for cancer patients. Eur J Cancer 2010;
46(16): 2896-2904.
86
Fan BF. Postmarketing surveillance study of OxyContin tablets for relieving moderate to
severe postherpetic neuralgia pain. Oncology 2008; 74 Suppl 1: 66-71.
87
Farrar JT, Polomano RC, Berlin JA, Strom BL. A comparison of change in the 0-10 numeric
rating scale to a pain relief scale and global medication performance scale in a short-term
clinical trial of breakthrough pain intensity. Anesthesiology 2010; 112(6): 1464-1472.
88
Fassoulaki A, Melemeni A, Paraskeva A, Siafaka I, Sarantopoulos C. Postoperative pain
and analgesic requirements after anesthesia with sevoflurane, desflurane or propofol.
Anesth Analg 2008; 107(5): 1715-1719.
89
Feng X, Lin SQ, Chen Y, Wu XJ. [Effect of postoperative analgesia with flurbiprofen axetil
and sufentanyl on metabolism of surgical patients with intestinal carcinoma]. Nan Fang Yi
Ke Da Xue Xue Bao 2007; 27(10): 1567-1569.
90
Feng Y, Ju H, Yang B, An H. Effects of a selective cyclooxygenase-2 inhibitor on postope-
rative inflammatory reaction and pain after total knee replacement. J Pain 2008; 9(1):
45-52.
91
Ferguson SE, Malhotra T, Seshan VE, Levine DA, Sonoda Y, Chi DS, Barakat RR, Abu-Rust-
um NR. A prospective randomized trial comparing patient-controlled epidural analgesia
to patient-controlled intravenous analgesia on postoperative pain control and recovery
after major open gynecologic cancer surgery. Gynecol Oncol 2009; 114(1): 111-116.
92
Fine PG, Messina J, Xie F, Rathmell J. Long-term safety and tolerability of fentanyl buccal
tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic
pain: an 18-month study. J Pain Symptom Manage 2010; 40(5): 747-760.
93
Fink DJ, Wechuck J, Mata M, Glorioso JC, Goss J, Krisky D, Wolfe D... Gene therapy for
pain: results of a phase I clinical trial. Ann Neurol 2011; 70(2): 207-212.
94
Fisher A, Watling M, Smith A, Knight A. Pharmacokinetic comparisons of three nasal
fentanyl formulations; pectin, chitosan and chitosan-poloxamer 188. Int J Clin Pharmacol
Ther 2010; 48(2): 138-145.
95
Fisher A, Watling M, Smith A, Knight A. Pharmacokinetics and relative bioavailability of
fentanyl pectin nasal spray. Int J Clin Pharmacol Ther 2010; 48(12): 860-867.
96
Fizazi K. Oral presentation at 46th ASCO meeting 2010. Chicago IL; 6.6.2012; Abstract
LBA4507.
97
Forastiere E, Sofra M, Giannarelli D, Fabrizi L, Simone G. Effectiveness of continuous
wound infusion of 0.5% ropivacaine by On-Q pain relief system for postoperative pain
management after open nephrectomy. Br J Anaesth 2008; 101(6): 841-847.
98
FORBES K. Opioids in Cancer pain. Oxford, New York, Oxford University Press 2007;
99
Freye E, Anderson-Hillemacher A, Ritzdorf I, Levy JV. Opioid rotation from high-dose
morphine to transdermal buprenorphine (Transtec) in chronic pain patients. Pain Pract
2007; 7(2): 123-129.
Literaturverzeichnis